Immune Oncology (IO) Drugs Testing
The Tumor Microenvironment (TME) has a key role in Solid Tumor Therapy Screening. The 3D TME-aligned model recapitulates original tumor microenvironment and promotes naïve behavior of tumor and immune cells. The pre-activation step of expanded autologous Tumor Infiltrate Lymphocytes (TILs) through incubation with bispecific antibodies potentializes tumor lysis driven by Immune Oncology (IO) Drugs. The cell retrieval at the end of treatment allows full mode of action characterization by FCM and description of genetic basis of resistance.

Tumor
Dissociation


Tumor Cells
TILs


Bispecific Antibodies
T-Cells
Activation

- Optional Step
IO Drugs Therapy




Tumor Cells

hMSC factors

T-Cells / TILs

Solid Tumor Sample
FCM Profiling
Rapid TILs
Expansion
TILs Activation
Step
Vivia 3D
TME-aligned Model
Cells Retrieval
& FCM Readout
Ex-vivo IO Drugs Screening:
TME-aligned IO Model

- Up to 7 colour markers – full cell profiling
- Good statistics & reproducibility
- Low time consuming
- FACS sorting functionally relevant cells
- Molecular on all or cell subsets
- MoA, signaling
- Epigenetic readouts
Solid Tumor Sample

Tumor
Dissociation
FCM Profiling


Rapid TILs Expansion


TILs Activation Step
- Optional Step
Bispecific Antibodies
T-Cells
Activation

Vivia 3D
TME-aligned
Model
TME-aligned
Model
IO Drugs Therapy




Tumor Cells

hMSC factors

T-Cells / TILs
Cells Retrieval
& FCM Readout
& FCM Readout

Ex-vivo IO Drugs Screening:
TME-aligned IO Model
TME-aligned IO Model

- Up to 7 colour markers – full cell profiling
- Good statistics & reproducibility
- Low time consuming
- FACS sorting functionally relevant cells
- Molecular on all or cell subsets
- MoA, signaling
- Epigenetic readouts